Secondary infection of common skin conditions including eczema: antimicrobial prescribing
In development [GID-NG10135] Expected publication date: 02 March 2021
Search results
669 results
-
-
Tobacco: preventing uptake, promoting quitting and treating dependence (update)
In development [GID-NG10086] Expected publication date: 01 September 2021
-
Stye: antimicrobial prescribing
In development [GID-NG10167] Expected publication date: TBC
-
Blepharitis: antimicrobial prescribing
In development [GID-NG10168] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Clostridioides difficile infection: antimicrobial prescribing
In development [GID-NG10144] Expected publication date: 23 July 2021
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 11 February 2021.
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 January 2021.
-
Anakinra for treating active Stills disease [ID1463]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 27 January 2021.
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 12 February 2021.
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 16 February 2021.
-
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
In development [GID-NG10113] Expected publication date: 19 January 2022
-
Safeguarding adults in care homes
In development [GID-NG10107] Expected publication date: 10 February 2021
-
Advocacy services for adults with health and social care needs
In development [GID-NG10156] Expected publication date: TBC
-
Adults with complex needs: social work interventions including assessment, care management and support
In development [GID-NG10145] Expected publication date: 27 April 2022
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 27 September 2021
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 10 May 2022
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: 02 June 2021
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Proposed [GID-TA10667] Expected publication date: TBC
-
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Proposed [GID-TA10599] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Proposed [GID-TA10604] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)
Proposed [GID-TA10279] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Proposed [GID-TA10346] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Proposed [GID-TA10298] Expected publication date: TBC
-
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]
Proposed [GID-TA10736] Expected publication date: TBC
-
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]
Proposed [GID-TA10753] Expected publication date: TBC
-
Remdesivir for treating COVID-19 [ID3808]
Proposed [GID-TA10721] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Proposed [GID-TA10716] Expected publication date: TBC
-
Mepolizumab for treating hypereosinophilic syndrome [ID3749]
Proposed [GID-TA10755] Expected publication date: TBC
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
Proposed [GID-TA10714] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
Amivantamab for non-small cell lung cancer [ID3836]
Proposed [GID-TA10729] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
Proposed [GID-TA10658] Expected publication date: 20 October 2021
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC